Austin Health

Title
Advanced Glycation End Products and Inflammation in Type 1 Diabetes Development.
Publication Date
2022-11-04
Author(s)
Du, Chenping
Whiddett, Rani O
Buckle, Irina
Chen, Chen
Forbes, Josephine M
Fotheringham, Amelia K
Subject
RAGE
autoimmunity
dietary AGEs
type 1 diabetes
Type of document
Journal Article
OrcId
#PLACEHOLDER_PARENT_METADATA_VALUE#
0000-0002-5459-5519
0000-0002-7486-3509
0000-0003-2104-534X
0000-0002-5595-8174
0000-0002-3213-8923
DOI
10.3390/cells11213503
Abstract
Type 1 diabetes (T1D) is an autoimmune disease in which the β-cells of the pancreas are attacked by the host's immune system, ultimately resulting in hyperglycemia. It is a complex multifactorial disease postulated to result from a combination of genetic and environmental factors. In parallel with increasing prevalence of T1D in genetically stable populations, highlighting an environmental component, consumption of advanced glycation end products (AGEs) commonly found in in Western diets has increased significantly over the past decades. AGEs can bind to cell surface receptors including the receptor for advanced glycation end products (RAGE). RAGE has proinflammatory roles including in host-pathogen defense, thereby influencing immune cell behavior and can activate and cause proliferation of immune cells such as islet infiltrating CD8+ and CD4+ T cells and suppress the activity of T regulatory cells, contributing to β-cell injury and hyperglycemia. Insights from studies of individuals at risk of T1D have demonstrated that progression to symptomatic onset and diagnosis can vary, ranging from months to years, providing a window of opportunity for prevention strategies. Interaction between AGEs and RAGE is believed to be a major environmental risk factor for T1D and targeting the AGE-RAGE axis may act as a potential therapeutic strategy for T1D prevention.
Link
Citation
Cells 2022; 11(21)
Jornal Title
Cells
ISSN
2073-4409

Files:

NameSizeformatDescriptionLink